BioAge Labs, Inc. Share Price & Technical Analysis
BIOA · $16.20 (-2.47%)
Healthcare / Drug Manufacturers - Specialty & Generic
$16.20
-2.47%
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibi…
Price chart
Seasonality
May has 0 positive and 2 negative years (last 3 years shown)
-2% return in May, -7% avg return in past 3 year May month.
41% return in 2026, 7% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 42% | 19% | -12% | -5% | -2% | – | – | – | – | – | – | – | 41% |
| 25 | -22% | 0% | -19% | 11% | -7% | 3% | 7% | 11% | 20% | 29% | 27% | 40% | 100% |
| 24 | – | – | – | – | – | – | – | – | -8% | 12% | -21% | -69% | -86% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$793.48M
P/E ratio
—
52W high
$24.00
52W low
$3.79
Volume
5,81,541
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BioAge Labs, Inc. share price today?
- BioAge Labs, Inc. (BIOA) last traded around $16.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BIOA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BIOA. Download the app for real-time alerts.
- How can I analyze BioAge Labs, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.